Predominant Stroma-Rich Feature in Hyaline Vascular Variant of Castleman Disease Is Associated With Paraneoplastic Pemphigus.


Journal

American journal of clinical pathology
ISSN: 1943-7722
Titre abrégé: Am J Clin Pathol
Pays: England
ID NLM: 0370470

Informations de publication

Date de publication:
05 08 2020
Historique:
pubmed: 28 5 2020
medline: 21 10 2020
entrez: 28 5 2020
Statut: ppublish

Résumé

We aimed to describe the clinical and histopathologic features of Castleman disease (CD), particularly emphasizing its associations with paraneoplastic pemphigus (PNP) and prognosis. We retrospectively enrolled 123 CD patients at our center. Clinical, pathologic, and laboratory data were reviewed. Fifty percent of the patients had PNP. Compared with those without PNP, patients with PNP-associated CD had more hyaline vascular (HV) variants (83.9% vs 57.4%), fewer mixed cellular variants (16.1% vs 24.6%), and no plasmacytic variants (0% vs 18.0%). Thirty-eight of 87 patients with the HV variant of CD (HV-CD) had stroma-rich (SR) features, and the incidence rate was higher in those with PNP-associated CD than in those without PNP (48.4% vs 13.1%, P < .001). The SR variant was associated with higher PNP-associated IgG titers than SR absence before surgery (median 1:160 vs 1:80, P = .019) or after surgery (median 1:160 vs 1:40, P = .013). The SR variant was also an unfavorable prognostic factor for CD survival in univariate analysis. The 3-year survival rates were 47.5% among those with PNP and 87.7% among those without PNP (P < .001). PNP is associated with specific subtypes of CD and affects survival. The SR variant of HV-CD positively correlates with the incidence of PNP.

Identifiants

pubmed: 32459333
pii: 5847646
doi: 10.1093/ajcp/aqaa053
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

403-413

Informations de copyright

© American Society for Clinical Pathology, 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Leyi Wang (L)

Department of Dermatology, Peking University First Hospital, Beijing, China.
National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.

Lin Nong (L)

Department of Pathology, Peking University First Hospital, Beijing, China.

Furong Li (F)

Department of Dermatology, Peking University First Hospital, Beijing, China.
National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.

Xue Wang (X)

Department of Dermatology, Peking University First Hospital, Beijing, China.
National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.

Rui Wang (R)

Department of Dermatology, Peking University First Hospital, Beijing, China.
National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.

Xixue Chen (X)

Department of Dermatology, Peking University First Hospital, Beijing, China.
National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.

Ping Tu (P)

Department of Dermatology, Peking University First Hospital, Beijing, China.
National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.

Yujun Dong (Y)

Department of Hematology, Peking University First Hospital, Beijing, China.

Ting Li (T)

Department of Pathology, Peking University First Hospital, Beijing, China.

Xuejun Zhu (X)

Department of Dermatology, Peking University First Hospital, Beijing, China.
National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.

Mingyue Wang (M)

Department of Dermatology, Peking University First Hospital, Beijing, China.
National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH